Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma

OBJECTIVE: The objective of this study was to evaluate the efficacy and safety of icotinib in patients with brain metastases (BMs) from lung adenocarcinoma. PATIENTS AND METHODS: Clinical data of 28 cases with BMs from lung adenocarcinoma were retrospectively analyzed. All the patients took 125 mg i...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jianping, Liu, Xiaoyan, Yang, Sheng, Zhang, Xiangru, Shi, Yuankai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876100/
https://www.ncbi.nlm.nih.gov/pubmed/27274284
http://dx.doi.org/10.2147/OTT.S102472
Descripción
Sumario:OBJECTIVE: The objective of this study was to evaluate the efficacy and safety of icotinib in patients with brain metastases (BMs) from lung adenocarcinoma. PATIENTS AND METHODS: Clinical data of 28 cases with BMs from lung adenocarcinoma were retrospectively analyzed. All the patients took 125 mg icotinib orally three times a day. Progression of disease, intolerable adverse reactions, and number of deaths were recorded. RESULTS: For all the patients, the remission rate of icotinib was 67.8% and the disease control rate was 96.4%. The median overall survival time of patients was 21.2 months, and the median progression-free survival time of patients was 10.9 months. Only mild adverse events of grade 1/2 were observed during the treatment. CONCLUSION: Icotinib was an effective and safe strategy to treat patients with BMs from lung adenocarcinoma.

Ejemplares similares